🇺🇸 FDA
Pipeline program

JNJ-17000139, JNJ-63723283, JNJ-63723283

17000139BLC2001

Phase 2 small_molecule active

Quick answer

JNJ-17000139, JNJ-63723283, JNJ-63723283 for Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials